CommercialCoverageMedium impact
08.00.74y, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
IBX has updated their pharmacy policy for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors. This affects billing and coverage for eye injection treatments commonly used for macular degeneration and diabetic retinopathy.
Action Required
By April 1, 2025: Review the complete updated policy at the IBX website to identify specific changes to prior authorization requirements, covered drugs, or documentation for VEGF eye injections. Update billing procedures and prior authorization workflows for ophthalmology services accordingly.